sorafenib has been researched along with Adverse Drug Event in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (9.09) | 29.6817 |
| 2010's | 41 (74.55) | 24.3611 |
| 2020's | 9 (16.36) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Andrade, AC; Castro, ACG; Farias, JPF; Garicochea, B; Gil, RA; Jácome, AA; Lessa, MAO; Lima, FMT; Moraes, ED; Prolla, G; Silva, MHCR; Vasconcelos, JPS | 1 |
| Brandi, G; Calabrò, C; Carloni, R; Cusmai, A; Laforgia, M; Oreste, D; Palmiotti, G; Ricci, AD; Rizzo, A; Sollitto, M; Ungaro, V | 1 |
| Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A | 1 |
| El-Gazzar, MGM; El-Hazek, RMM; El-Sabbagh, WA; Fadel, NA; Zaher, NH | 1 |
| Casadei-Gardini, A; Foschi, FG; Granito, A; Ielasi, L; Negrini, G; Orsi, G; Piscaglia, F; Renzulli, M; Rovesti, G; Tovoli, F | 1 |
| Baldan Ferrari, G; Berlofa Visacri, M; Coelho França Quintanilha, J; Cursino, MA; de Godoy Torso, N; de Oliveira Guarnieri, JP; Moriel, P; Oliveira Vaz, C; Passos Lima, CS; Pereira, TT; Sampaio Amaral, L | 1 |
| Carceller, F; Marshall, LV; Pearson, H | 1 |
| Honeywell, RJ; Mammatas, LH; Menke-van der Houven van Oordt, CW; Peters, GJ; Rovithi, M; Swart, EL; Verheul, HMW; Zandvliet, AS | 1 |
| Dame, K; Grafton, F; Loewke, K; Maddah, M; Mandegar, MA; Ribeiro, AJS | 1 |
| Chen, Y; Deng, L; Fan, Z; Huang, F; Huang, X; Jiang, L; Li, X; Liang, X; Lin, R; Liu, H; Liu, Q; Luo, X; Shi, P; Sun, J; Tu, S; Wang, Y; Wang, Z; Xu, N; Xu, Y; Xuan, L; Yu, C; Zhou, X | 1 |
| Lee, WJ; Tam, HP | 1 |
| Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J | 1 |
| Braiteh, F; Burris, H; Cohn, AL; Foster, P; Kelley, RK; Lee, Y; Spira, A; Su, WC; Van Cutsem, E; Verslype, C; Vogelzang, N; Yang, TS | 1 |
| Buder, R; Galle, PR; Ganten, TM; Gerken, G; Göhler, T; Koschny, R; Malfertheiner, P; Schott, E; Stauber, RE; Walther, M | 1 |
| Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L | 1 |
| Bai, T; Chen, J; Li, LQ; Li, ZH; Qi, LN; Wu, FX; Yang, TB; Ye, JZ; Zhu, SL; Zou, L | 1 |
| He, J; Jia, B; Yan, J; Yang, J | 1 |
| Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J | 1 |
| Jian, W; Li, C; Sun, X; Xie, F; Zhang, K | 1 |
| Fu, Y; Liang, J; Lin, L; Wei, X; Xu, W | 1 |
| Chow, ML; Compoginis, G; Crew, AB; Ochoa, MT; Salame, N | 1 |
| Alonzo, T; Aplenc, R; Barakat, LP; Gerbing, R; Johnston, DL; Kolb, EA; Meshinchi, S; Nagarajan, R; Sung, L | 1 |
| Boni, C; Bozzarelli, S; Carnaghi, C; Chiara Banzi, M; Chiara Tronconi, M; Cortesi, E; Fagiuoli, S; Fanello, S; Foa, P; Giordano, L; Personeni, N; Pressiani, T; Rimassa, L; Romano Lutman, F; Rota Caremoli, E; Salvagni, S; Santoro, A | 1 |
| Prado, CM | 1 |
| Ishizuka, O; Nishizawa, O; Suzuki, H; Suzuki, T; Ueno, M | 1 |
| Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J | 1 |
| He, J; Li, YS; Wei, LX; Wei, X; Xu, F; Yu, FF; Zhang, TY; Zhang, XJ | 1 |
| Balakan, O; Berk, V; Bilici, A; Buyukberber, S; Cinkir, HY; Demirci, U; Erdogan, B; Gumus, M; Kaplan, MA; Oflazoglu, U; Oksuzoglu, B; Ozdemir, N; Ozkan, M; Ozturk, T; Tastekin, D; Tonyali, O; Turkmen, E; Unal, OU; Uyeturk, U; Yasar, N | 1 |
| Berlin, J; Cardin, DB; Chan, E; DeVore, R; Goff, L; Grigorieva, J; Holloway, M; Li, CI; McClanahan, P; Meyer, K; Schlabach, L; Shyr, Y; Winkler, C | 1 |
| Ara, M; Pastushenko, E | 1 |
| Barbara, M; Basso, M; Biolato, M; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Della Corte, C; Grieco, A; Iavarone, M; Maida, M; Vavassori, S | 1 |
| Addario, L; Caporaso, N; Cordone, G; de Stefano, G; Di Costanzo, GG; Farella, N; Imparato, M; Lampasi, F; Lanza, AG; Tortora, R | 1 |
| Aldridge, J; Atkins, MB; Conley, C; Flaherty, KT; Giobbie-Hurder, A; Hodi, FS; Ibrahim, N; Lawrence, DP; McDermott, DF; Mier, JW; Sullivan, RJ | 1 |
| Adachi, M; Akaza, H; Gemma, A; Hyodo, I; Iijima, M; Inuyama, L; Itoh, H; Okayama, Y; Oya, M; Sunaya, T | 1 |
| Bodoky, G; Buehlmann, M; Demeter, G; Dufour, JF; Feilchenfeldt, J; Horber, D; Koeberle, D; Lakatos, G; Li, Q; Montemurro, M; Peck-Radosavljevic, M; Rauch, D; Ribi, K; Roth, AD; Saletti, P; Samaras, P; Tschanz, B; Wagner, AD | 1 |
| Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK | 1 |
| Han, KH; Han, SY; Heo, J; Kim, DY; Kim, HJ; Kim, YH; Kweon, YO; Lee, BS; Lee, HC; Lee, WS; Lim, HY; Ryoo, BY; Um, SH; Woo, HY; Yoon, JH; Yoon, SK | 1 |
| Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK | 1 |
| Bai, W; Cai, H; Fan, D; Han, G; Liu, L; Niu, J; Wang, E; Wang, W; Xia, D; Xia, J; Yang, M; Yin, Z; Zhang, L; Zhang, Z; Zhao, Y | 1 |
| Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP | 1 |
| Delgado-Fernández, M; Galindo, MJ; García, MA; Garcia-Deltoro, M; Ibarra, S; Merchante, N; Merino, E; Mínguez, C; Montero-Alonso, M; Pineda, JA; Revollo, B; Rivero-Juárez, A; Rodríguez-Arrondo, F; Romero-Palacios, A; Téllez, F | 1 |
| Alasker, A; Guevremont, C; Karakiewicz, PI | 1 |
| Atkins, MB; Humphreys, BD | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY | 1 |
| Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN | 1 |
| Cao, L; Choyke, P; Force, J; Giaccone, G; Gutierrez, M; Keen, C; Kelly, RJ; Kummar, S; Lopez-Chavez, A; Raffeld, M; Rajan, A; Steinberg, SM; Turkbey, B; Wright, JJ; Xi, L; Yu, Y | 1 |
| Bollag, G | 1 |
| Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C | 1 |
| Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H; Sakai, I | 1 |
| Cagan, RL; Dar, AC; Das, TK; Shokat, KM | 1 |
| Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY | 1 |
| Bhojani, N; Hutterer, G; Jeldres, C; Karakiewicz, PI; Oudard, S; Patard, JJ; Patenaude, F; Perrotte, P; Suardi, N | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Berthold, DR; Chin, S; Knox, JJ; Moore, MJ; Riechelmann, RP; Tannock, IF; Wang, L | 1 |
9 review(s) available for sorafenib and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Topics: Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2021 |
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis.
Topics: Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2023 |
Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Liver Neoplasms; Sorafenib | 2020 |
Body composition in chemotherapy: the promising role of CT scans.
Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2013 |
Risk of treatment-related mortality with sorafenib in patients with cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Survival Rate | 2014 |
Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2014 |
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
16 trial(s) available for sorafenib and Adverse Drug Event
| Article | Year |
|---|---|
Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study.
Topics: Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pulse Therapy, Drug; Sorafenib; Treatment Outcome | 2020 |
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
Topics: Adolescent; Adult; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2020 |
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Hepatocellular; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2017 |
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2017 |
Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group.
Topics: Adolescent; Bortezomib; Child; Child, Preschool; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Myeloid, Acute; Male; Quality of Life; Self Report; Sorafenib | 2019 |
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Surveys and Questionnaires; Treatment Outcome | 2014 |
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Quinazolines; Sorafenib | 2014 |
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Spain; Survival Analysis; Treatment Outcome | 2017 |
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzoquinones; Clinical Trials, Phase II as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lactams, Macrocyclic; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Genes, ras; Humans; Lung Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib | 2011 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2013 |
Sorafenib for metastatic renal cancer: the Princess Margaret experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis | 2008 |
30 other study(ies) available for sorafenib and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fibromatosis, Aggressive; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2023 |
Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact.
Topics: Animals; Carcinoma, Hepatocellular; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Liver Neoplasms; Mice; Myocytes, Cardiac; Sorafenib; Sulfapyridine; Vascular Endothelial Growth Factor Receptor-2 | 2023 |
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Duration of Therapy; Female; Humans; Italy; Learning Curve; Liver Neoplasms; Male; Medication Therapy Management; Middle Aged; No-Observed-Adverse-Effect Level; Off-Label Use; Practice Patterns, Physicians'; Sorafenib; Survival Analysis | 2019 |
Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Oxidative Stress; Prospective Studies; Quality of Life; Sorafenib; Surveys and Questionnaires; Treatment Adherence and Compliance; Treatment Outcome | 2020 |
Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
Topics: Antineoplastic Agents; Biological Assay; Cardiotoxicity; Cells, Cultured; Deep Learning; Doxorubicin; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Hepatocytes; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Sorafenib; Tamoxifen; Toxicity Tests | 2020 |
Painful skin reaction.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Emergency Service, Hospital; Hand-Foot Syndrome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib | 2017 |
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2017 |
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2017 |
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Blood Glucose; China; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Hyperglycemia; Incidence; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Registries; Sorafenib | 2017 |
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Safety; Sorafenib; Treatment Outcome | 2018 |
Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2018 |
Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Sorafenib; Sunitinib | 2018 |
Sorafenib Toxicity Mimicking Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Hypersensitivity Syndrome; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Metastasis; Sorafenib | 2019 |
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asia; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; United States | 2014 |
Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Turkey | 2013 |
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Risk Assessment; Sorafenib; Survival Analysis; Withholding Treatment | 2015 |
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Management; Drug-Related Side Effects and Adverse Reactions; Early Detection of Cancer; Europe; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pacific Islands; Phenylurea Compounds; Registries; Sorafenib; Young Adult | 2016 |
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Republic of Korea; Sorafenib; Treatment Outcome | 2016 |
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2017 |
Rapid development of hypertension by sorafenib: toxicity or target?
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Pressure; Drug Delivery Systems; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Mice; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure | 2011 |
Setting up a kinase discovery and development project.
Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Discovery; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Enzyme Assays; Humans; Indoles; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Solubility; Sorafenib; Structure-Activity Relationship; Sulfonamides | 2012 |
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib; Survival Analysis | 2011 |
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
Topics: Animals; Benzenesulfonates; Cell Transformation, Neoplastic; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Extracellular Signal-Regulated MAP Kinases; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Molecular Targeted Therapy; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Polypharmacy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays | 2012 |